Drug maker Ipca Laboratories today reported a fall of 65 per cent in its net profit for the fourth quarter ended March 31 to Rs 7.90 crore.
The company had a net profit of Rs 22.64 crore during the January-March quarter a year earlier, Ipca Lab said in a filing to the Bombay Stock Exchange.
However, the pharmaceutical company reported a rise in its total income during the fourth quarter to Rs 317.5 crore as against Rs 249.9 crore of the corresponding period a year ago.
The company declared a final dividend of Rs 4 per share for the financial year ended March 31, 2009.
For the financial year ended March 31, the company posted a net profit of Rs 91.22 crore, down 35 per cent as against Rs 141.12 crore of FY08.
Shares of Ipca Lab slipped over 4 per cent to hit its lower trading limit of Rs 486.70 on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app